ReviewClinical interventions in aging2009
Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer.
Review in Clinical interventions in aging, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Unrecognized kinetics of serum testosterone: impact on short-term androgen deprivation therapy for prostate cancer.Yonsei medical journal · 2014Trial
- Predicting drug release from polymeric long-acting injectables using a machine learning approach to decode formulation-performance relationships.Drug delivery and translational research · 2026Article
- Population Pharmacokinetic Modeling and Simulation for Dose Optimization of GB-5001, a Long-Acting Intramuscular Injection of Donepezil, in Healthy Participants.Neurology and therapy · 2024Article
- Diffuse Maculopapular Dermatitis Associated With Leuprorelin Acetate Androgen Deprivation Therapy.Cureus · 2024Article
- Use of a biomimetic hydrogel depot technology for sustained delivery of GLP-1 receptor agonists reduces burden of diabetes management.Cell reports. Medicine · 2023Article
- Adherence to oral hormonal therapy in advanced prostate cancer: a scoping review.Therapeutic advances in medical oncology · 2023Article
- ELIGANT: a Phase 4, interventional, safety study of leuprorelin acetate (ELIGARDTranslational andrology and urology · 2022Article
- Long-term Effects of Androgen Deprivation in a Patient with Spinal and Bulbar Muscular Atrophy - A Case Report with 14 Years of Follow-up.Internal medicine (Tokyo, Japan) · 2019Article
- Review
- Clinical pharmacology and regulatory consequences of GnRH analogues in prostate cancer.European journal of clinical pharmacology · 2014Review
- Six-month leuprorelin acetate depot formulations in advanced prostate cancer: a clinical evaluation.Clinical interventions in aging · 2013Review
- Leuprolide acetate 1-, 3- and 6-monthly depot formulations in androgen deprivation therapy for prostate cancer in nine European countries: evidence review and economic evaluation.ClinicoEconomics and outcomes research : CEOR · 2013Article
- Durable remission of leptomeningeal metastases from hormone-responsive prostate cancer.Medical oncology (Northwood, London, England) · 2012Article
- Targeted polymeric therapeutic nanoparticles: design, development and clinical translation.Chemical Society reviews · 2012Review
- Imaging of recurrent intramuscular granulomatous masses induced by depot injection of leuprorelin.Skeletal radiology · 2012Article
- Six-month gonadotropin releasing hormone (GnRH) agonist depots provide efficacy, safety, convenience, and comfort.Cancer management and research · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hormonal deprivation therapy is well established for the treatment of locally advanced and metastatic prostate cancer, as well as the adjuvant treatment of some patients with localized disease. Long-acting gonadotropin releasing hormone (GnRH) agonists have become a mainstay of androgen deprivation therapy, due to their efficacy, tolerability, and convenience of use. One-month, 3-month, and 4-month depot leuprorelin formulations are well established and widely used to this end. Recently, a 6-month depot leuprorelin has been approved for use in advanced and metastatic prostate cancer patients. With similar efficacy and side effect profiles to earlier formulations, 6-month depot leuprorelin is a convenient treatment option for these patients. This review will highlight the role of GnRH agonists in the treatment of prostate cancer with a focus on the clinical efficacy, pharmacology, and patient-focused outcomes of the newer 6-month 45 mg depot leuprorelin formulation in comparison to available shorter-acting products.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.